Cost and quality of life: Thrombolysis and primary angioplasty  by Goldman, Lee
-. -:Xn cost&&cti~n~~ analysis,. an intervention’s effeti tin 
ws+k compared with $sef&ct ori otitcoqes (t-j). The .re+ 
is co&xmly expre&ed as a ratio,with-changes in cost ‘iti the 
numerator and 3~ zz@s in ihe measure of e&ctiveness in the 
deLodnator. 
Cos@‘are commo&.6ea&d in dqlI~+ and usu&y refer 
to the net dir& costs of the intdrveni~~n arid the. d&ease- 
related C+Z t&it it may: &Iuce & avert. i%r example, a: 
thronrbolytic s&t would have 3% owfi custs, arid its e$xts on. 
suetsequent c iavassxllar care, imA@ng cardiic procedures 
and strokes; +ld be c&ulated~’ More implicated a&iyses 
would include ,other,, medical.. &tAW such aS the, &w&ream 
#Et of i”- cjdcysteeto&y ‘that might +Su$ly be necessixry 
fwsomeuncsitose &was savedb~,thrOmbO!y&. &mimtir~ 
ambitious Analyses would consider,stich c&+-as the estimated 
fzdfbts of the th~mbolysis on @tlture &stodial care for possible 
Alzhehner’s disqse. Finally; the- an&&g +@~t .qmsidery ~41 
. .:: ‘,‘. : ,.‘, 
.- 
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medical costs and in.&rect cu@s,‘such as da@ of work hxt,’ the 
ecuno& impact of cur&t and fut& iline& on the patient’s 
famiIy? and any effects on the social se+-@ system. Because 
many of the assumptions required for these more detailed 
analyses are so uncertain, most cost-effectiveness anaIyses 
concentrate on disease-related costs. 
Costs are not the same as prices or charges. Unlike prices or 
ehtges, which tend to be reasonably constant regardless crf 
volume, CcrSts vary dramatic+ with volume. The incremental 
cost of an additional test or procedure may be relativeiy small 
because the infrastructure re@ired to provide it is already in 
place and’ will have a ,constant cost -regardIes% of whether the 
hacremental. procedure is performed. At some point, however, 
an. intiase in v#ine will require A, chti&e ,in the i#rastn& 
ture %hd ti,incr@ase in.Gxed’cdsts: ’ ‘I’ .’ 1. : ‘. ; 
The effectiieness of art intervention is often m&&red in 
iunits such as lives s&x$, years of life saved or qua&y-adjusted 
yean rrf !il’t: saved. Any .adjustment foi quality requires an 
:+preciatiofi’of how individuais with the condition &uld ialue 
jtheir qtlalib df life, Avariety of,*etho+ & available to make 
)such measure&&s, but none is perfect. ‘, ‘.,: 
Mtit studies of c&d& interventions for acute condaions, 
such as a$e m$ocardi@ infarction, haye relied &n analfles .I 
that &mpz~ costi with ye@ of “Iif: save’d.Althou& analyses,. 
that consider $mIir@jWed yeati of Iif? wo@d be preferable, 
empiric data for. quality ~djys$@zt: &en have noi b&n 
.re@b!e’ enough t& & .incorporated into su& ‘walyses at ihe 
.piesent time.: ,, :. _. i 
Ifi mod anmes, imyedi+ costs @id effectiveness c;n,be 
msasu&d now, but future costs’or promises,of benefits are less 
tirtain. T‘llerefore, cost-effectiveness analyses wmmor2y ‘Idis- 
c&uI~‘~ fwure ~ci1~4.s and future’ t enefiti; Usually at ti rate’ of 
’ abolit 5% per year. ThL principle explains why mtiy peven- 
tive program% which inust spenti &:!ars now in the hope of 
preventing disease in, ,+e future, may not have favorable 
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cdt~effectiveneis ratios .uuIess the prevent itie: intervention & 
inexpensive or the patients are at’s&i@ently high risk. 
.,In cost-eff~ctiveness’,analysk it is not pwsibli to’find, the 
g&test possible ,benefit for the, lowest p&ibA,lk cost.. The 
analysis mu&t either strive t.o determine the resti- avtiilable 
and: then find the greatest possible eflectivenes that can be . 
@urcha&d for the& resources, or determine the desired effec- 
tiveness and then find :the lowest cost kay to achieve it’, Wiih 
either approach, a cost-effectiveness ratio can be determined, 
and it must be compared against what society may be willing to 
pay. 4 common benchmark is the -$3QOOQ‘year of life saved 
by. the ‘endistage renal disease,’ program’. Of ,note is: tliat ‘this 
figure has remained constant dver the past decade or more, 
because reimbursements in thai program have not increased 
with inflation (4). 
A cost-effective&s analysis.sh&ld also include sensitivity 
analyses in which each of the key assumptions is varied to see 
ii reasonable diierences in any of them will have a substantial 
impact on the overall condusion of- the ana’lysis. Analyses 
whose conclusions do not var$ .substsa,ively based on such 
changes ih estimates are much more mnvincing.than tho& !hat 
do. 
Thrombolysis 
The relative benefit of thro@olytic therapy varies directly 
with the’ delay between the ,onSet bf sytiptoms and ‘the 
institution of thirapy. Pooled data suggest about a 32% 
reduction in mortality if treatment is instituted in the first 2 to 
3 h after the onset of symptoms, a 25% reduction in mortality 
if therapy is instituted within abcrut. 2 to b h after she onset of 
.symptoms and about a-15% reduction in mortality if therapy is 
instituted between -6 and 12 to 24 h after the onset of 
sympt?ms (5), 
me first major cost-e&&en@ anal)& of thrtimbolysis 
: {6) noted that’the tippr&nate c&t fof each ad$i&al.person 
whq would ,survive 1 year or more &th thrombolysis wasvery 
reasonable for, large and modeiate-sized myocardial infarc- 
tio?s but less convincing’for ,smalI infarctions. The projected 
cost-effectiveness depended on the amount of ‘jeopardized. 
m+rdium; ttie time since o&et of sympW&s,. tlie time from 
treatment to .tht’:achieveinknt of reperfus’ion aPld the Q$e of 
p~tthrumboIy&c:tieat~ent ihe patients iv$re:,to receive, This 
and ktiot&er eariy analy& (7). did n6t try to calcul$e a,cost per 
year of ‘!ife saved, -the, riiost comnioti .tietric for ‘cost- 
effectiveu& analyses,. be&@& data: Were not yet &aitable 
regarding lon$erql outcomes afteqthr@mbolysis. ‘, 
.’ ;, MO+ recent!y, another:ana&is (Qfound that thromb$ysis 
ti:h streptr?kinase,had in estimated cost-e#ecti?ene& ratio cf 
about $21,OCX@%ar of life saved in paticn:sasold as Ml years df 
‘-age, !ng. it would bemore aftractive L in younger sul,jects. 
Although the e!dertyy receive I&s r&@e. benefit from thmm- 
boly& than y&nger patients with mydca~~jal infarct~un; tFeir 
~&s&fe risk of death from myoc+al infarction is much 
higher. A reduced retat& benefit multiplied hy a high& 
absolute risk yields a rather si&ar absolute immediate’btne- 
: . . ‘. : I’ : ,, 
fit fr& thrombol$& &~ecthel&s, -use the elderly jhhi 
a short& life expectancy &an young& patients. ,she cost- 
e&ti?eneti, ratip is still not, quite as,good. ’ ‘: .’ 
T& analysis “al&- d&notistrattid that ‘the ~0s: .c%i;;ttieness 
of thmmbolysistias rehtivtiiy i,ndepe,n+nt of whether tile, rate 
of stioke, W%s as high as. 2%’ and did et chtingc suhs~an~iatly 
tia&d on varying &umptiotis,about the co& of the: strok?. the 
risk of other bleeding contplications, :dr the cost bf titetidir:g 
complicatians. However, if .the thrombolytic agent cost U&Kl/ 
patient rather than the $200 average cost of streptokitiase, and 
the ,ixreased CFW were not associated with an? changes iri 
clinical otitcomes. the cost-effectiv~tiess ratio’&ould increak to 
about %45,WWyear~ of lifti saved .when compared with: no 
thlcjmbolysis (5). The cost-effectiveness of thrombolysis also 
depends on the location of the. infarct and the -degree of: 
certainty that the patient is having an acute myocardial infarc- 
tion with an occluded vessel (8). 
If accelerated tissue-type plasminogen activator (t-PA), 
results in an addidonal 12% reiative ‘reduction in mortal@ 
compared with that for streptokinase (9) hecause of higher 
repeifusion rates (HI), this increm&tal hrnefit would be 
accompanied by an increment of -$1,81H) in,costs (S,ll), which 
would approximately double the cost of throtibolytic treai- 
ment. including all induced cardiovascular costs. The abdi~ 
tional. 12% relative benefit from substituting accelerated t-PA 
for streptokinase would provide an absolute’ incremental ben- 
efit that is about brie-third &great as’the absolute-incremental. 
benefit that results from the 27% relative benefit that is 
achieved hy adding streptokinati to routine care. 
The estimated incremental COG yffestiveness ratio of strep- 
tokinase in nonelderly patients with .acut? myocardial infarc- 
tian ranges from -43,SOO (10). to $21,tHN) (5) per year of life 
saved. The estimated incremental cost-cffectibeness ratio of 
I-PA compared nith that for streptokinase ranges from 
-$16,OOi! Po $6O,OtWyeqr of lifti saGed,( 
Ariy estlmite of .the r?Iative cost-e!&iv&zss bf .kkel~r- 
ated t-PA compared with, streptol$ase depends critically on 
whether the benefits in the Globai Utilization of StreptoGnase 
and Tissue ;Ptasmi~ogen Activator for Occluded Coronary 
Arteries (GUSTO) trial are replicable’. 0~ the b&is-of yxqser- 
iinental evidence regarding the improvement, in patency: rates 
with such treatment both’ in GUSTO (13) and in other ‘s!$dies 
(!4), &seems likely that this tiew regimen does, in faGt;-c@&r 
such benefit. In patients with. smaller-mytirdial infarctio?s or 
in: patients !rcale@ ,J?ng after the tin@ of hmptoms, the 
,inCremental,oos~-effectiveness-ratio of ttc&ler$ed t-PA would 
bej’higher than in dther patients. .. .i .:- : 
.‘. 
.: ,’ :‘;Primaj Angi&b&ty . . 
.I%+ three .rimst, rezgen!. ragd”,..- -k&d controlled ,.trials ‘of 
prim+‘angioplasty (15-17) &&gest a.&!&~, O’;i zduction- 
in e8rly mortality &tes among patiknts treated. with this 
?rategy compared with &tine thrombolysi6 CTabte i). Of 
note is that this relaiive reduction in mortality wm greeter than 
the 25% or .,-so relative -.redLctio:~ reported’ in siudiis of 
‘thrombo~ as compared with +ndqmized eontrolked p+ient!; 
(4). It ab compares very favorably :With the - 17% r&tivc 
mortality xeduction -iichievcd by Hng ~hiombolysis .in the 
prehospital setting compared wit11 the i+hospital- setting, 
‘which results in about a l-h reduction in the delay between the 
onset af &mptoms and the administration of thrombofysiti (18) 
(Table 2). 
The trials ‘d primary an&pla+ty have found about a l-h 
delay. between hospital arrival. and the angiopfasty. If a l-h 
diifefencg in the time. to reperfusion correlates with about a 
17% mortality difFer&ce, primary angiopftity : would be ex- 
pect&J to be better than ihtravcnous thrombolyt& therapy.even 
if the $4ay we= increased from 1 h to 2 or 3 h, 
In the’ three most recent randomized trials of, primary 
hgiop&sty;the proce$ure rwmkd in coronary rep&u&on in 
93% to 98% of pa:ien@ (1.5-17). The success rate from primary : 
an@oph&y in tt&e ran&mized triaIs.was ubstantially higher 
th& in small rand&ized trials performed in theUnit States 
in 19fM (19) and ti -1. in ‘1989 (Zo), prob&~ because of 
impmvemknti in mgi@asty techniques. The Thrombolysis in 
&iyoeardial Infarction (TIMI) grade 3 perfitsion rate with 
dir@ an&oplasty was h&he< than with ‘t-PA (21); and it was 
+hicved quickly and without the risk of thrombolysis-re!atcd 
bledig. Success r&s of 88% to 98% (22-25)’ have been 
aahieved in other re&nt noru&d~mized : U.S. studies.:, $I- j 
.prcwed rqerhghn &arentlj explains the reduction ir’ t~rpr- 
tality. fspeciahy in the highest’risk patients. 
,! Patients treated #h primary angidplasty Itended tc’ have 
~hctrter ho.$*Qt! stays and lower In-hospitaj and! fi month 
f&~-up costs (1 S$6). Now uc:,.tk’ $ulysis of co+ did nut 
tie that new ficiIitiesV *ems, :or f#iqi- r&u; c :s would . . : 
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:,. 
,.’ 
” ., 
J.4cc Vd. 2% Ye. 7 ISupy:c-;rmlt) 
., 
.‘. ‘. :: Jutlc lw5:3Rs-4Ls~ :::. ,,: ;’ 
.:,I, ‘, .,, .. 
.I I. .‘, :: 
be rqyir& if the str&ea’of. primary an&@&y were b be 
extended .beyond. the small ~nur&r. of institutious that. cur- 
-r?& tiul$ perform it on $I emerg&& around-tb+clo# basis 
to the iarge ,numb$ of mrJ.it@ns that.trow rely on thrcimbol- 
y& .&the ~ferred:te’atment: 1. :’ ‘. ! 
If piimaty ang@plasty can achieve a 63% &at&f& red~?~Gon 
iri mo&litjl at no. ‘inckse in cost% then recommendations 
: regarding its use I+ not require arry ~q@ist&ted C.&&&W. 
Per&i, idditibnal data, it is hard NY- argue ‘againat primary 
angioplasty as the treatment qf choice in situations irr which it 
is a practical etitension of an existing system ,-that provides 
high-quality angiopiasty and on-site coronary artery bypass 
surgery. 
if current.data can & extrapoiated,hur n&ionol health care 
system should consider the @.Sibiiity of transfer for primary 
angioplasty rather than on-site thrombolysis-if such a sEraEef$Jf 
resulted in no more than a l- to 2-h delay, especially in the- 
highest risk patients. However; such a &rate&g tiou)d require 
empiric testing through ti randomized controlled trial before it 
could be widely recommended. A more diGcult issue is 
‘whether’ the, capabilities for a primary angiop+y should be 
extended to the large number of institutions that eurrenw 
cannot provide such care. It was recently estimated that only 
18% of hospitals in the United States can perform aizgioplasty 
(27), and even fewer can both perform it on an emergent basis 
and provide backup coronary artery bypass surgery. Primar) 
an&ioplasty may be performed in some hospitals witilorit’ 
‘on-site coronary artery byp&surgej with suceeaS rates .~nJi 
survival’ rates. that tie similar to what is wmnpkhed d L t% 
that have available o&site surgeq (22). Howe~r, ~tb:*&rger 
studies would be required before such an approac>, c&d 
become national policy. I 
The incremental expense of developing these fa&i’L. i .‘id 
training t&it staff would be far digerent from :he &st..s 
incurred at sites nhere thdse capabilities nIroitc]y T...:. Fm-Ger- 
rn; .k, the success rate of primary angtopbi.~ty 4s’ criL. ;I?; 
Je+tdent on -the $@I and the .volume of the operator, and 
there is no.evidence that the- results found ,in tie, high qualitj 
center&a? ha&, partici@yl in the published r@ls could be’ 
&ended IO all institutions. 
.., 
;. where &y-we ,N,m@ .; .’ 
inmy tipinion, ‘the e&ng randomiz&l ‘trials demo s?k& 
the..ben& Xpiimary angiopiasty uti& ideal circumst~&i;c.s. 
Future &do&red, triaL, should as-. whet;::: Ike’ Ma: 
required for “transfer to’ appropriate facilities ;,;y,h ~11 ‘i‘4 at 
least hong high risk patients with myocardial ,;~cr+&>e 
alternative, which would be to provide such services routir,~,~ 
in all hospit+,js less !ikoly td; be.a,cost-e&&e alternative ttt 
the current pc$icy.iwhich is to.administer thtimboiysis as 
rapidly ‘as’p&sible. : 
_’ ~How~about thrornbofysis? !f accelerated !-PA iS truly better 
than the taPA -regimeti used in previous randomized- ,tials 
Q&29), its cost-effe~~~~.ratio’r~atrve to ++&itmae till 
be reasontie (3~3)~ especially in higher risk patienta and those 
‘_ 
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